Method of inhibiting
View Patent ↗Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.
1. A method of treating a C. difficile infection in a subject, consisting of administering a therapeutically effective amount of a glycopeptide antibiotic to a subject having a C. difficile infection, thereby treating a C. difficile infection in a subject, wherein the glycopeptide antibiotic is oritavancin, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, or a mixture thereof.
2. The method of claim 1 , wherein C. difficile is a vegetative form of C. difficile , a C. difficile spore or a mixture of both.
3. The method of claim 1 , wherein the glycopeptide antibiotic is in the form of a pharmaceutical composition comprising the glycopeptide antibiotic and a pharmaceutically acceptable carrier or diluent.
4. The method of claim 1 , wherein said treating inhibits outgrowth of a C. difficile spore, inhibits growth of a vegetative form of C. difficile or inhibits C. difficile sporulation.
5. The method of claim 1 , wherein the therapeutically effective amount of the glycopeptide antibiotic is between about 5 and 30 mg/kg body weight.
6. The method of claim 1 , wherein said administering is BID for four days.
7. A method of preventing a C. difficile infection in a subject, consisting of administering to a subject exposed to C. difficile bacteria an amount of a glycopeptide antibiotic sufficient to prevent C. difficile infection, thereby preventing a C. difficile infection in a subject, wherein the glycopeptide antibiotic is oritavancin, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, or a mixture thereof.
8. The method of claim 7 , wherein C. difficile is a vegetative form of C. difficile , a C. difficile spore or a mixture of both.
9. The method of claim 7 , wherein said administering is via intravenous administration or oral administration.
10. The method of claim 7 , wherein the glycopeptide antibiotic is in the form of a pharmaceutical composition comprising the glycopeptide antibiotic and a pharmaceutically acceptable carrier or diluent.
11. The method of claim 7 , wherein said preventing inhibits outgrowth of a C. difficile spore, inhibits growth of a vegetative form of C. difficile or inhibits C. difficile sporulation.
12. The method of claim 7 , wherein the amount of a glycopeptide antibiotic sufficient to prevent C. difficile infection is between about 5 and 30 mg/kg body weight.
13. The method of claim 7 , wherein said administering is BID for four days.